Adragos Hub

Stay up-to-date with our latest news, blog articles, videos, and event announcements. Learn from business success stories and gain access to valuable e-books and resources.

Blog

Blog

->
News

News

->
Events

Events

->
Videos

Videos

->
Resources

Resources

->

Adragos Pharma Kawagoe signs basic agreement with Towa Pharmaceutical for strategic collaboration to support stable supply of off-patent medicines

April 15, 2026 Adragos Pharma Kawagoe K.K. (Headquarters: Kawagoe, Saitama; Representative Director and President: Masanori Kurogome) has signed a basic agreement with Towa Pharmaceutical Co., Ltd. (Headquarters: Kadoma, Osaka; President and CEO: Itsuro Yoshida) to establish a strategic collaboration aimed […]

Navigating Early-Stage Fill-Finish for Biologic Drug Products

A Strategic Guide to Navigating Early-Stage Fill-Finish for Biologics Optimising early-stage fill-finish for biologics begins at a point where resources are constrained, knowledge is incomplete, and regulatory scrutiny is intense. The central task is to convert a promising molecule into […]

Introducing Maisons-Alfort: Commercial-Scale PFS Manufacturing and Sterile Vial Production 

For pharma and biotech companies, selecting a sterile manufacturing partner is about more than equipment or capacity alone. It is about choosing a site that can combine reliable PFS manufacturing, sterile vial production, quality systems and operational support in a way that enables […]

Adragos Pharma finalizes the acquisition of Commercial-Scale Sterile Fill-Finish Manufacturing Site at Maisons-Alfort, France, from Sanofi

Munich, April 1, 2026 – Adragos Pharma, a global contract development and manufacturing organization (CDMO), today announced that it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of Europe’s largest manufacturing facilities for sterile […]

From Lab to Launch: De-Risking Small-Molecule Development at Our Adragos Athens Facility 

Why small-molecule development risk is often discovered too late  Small-molecule development does not usually fail because teams lack effort. It fails because risk is discovered too late. The cost then appears as rework, delayed approvals, or supply plans that collapse […]

GMP Analytical Laboratory and HPAPI Containment for Small-Molecule Development 

In small-molecule development, risk rarely appears as a single obvious event. It usually emerges through an atypical analytical result that cannot be defended, a stability trend that forces reformulation, a tech transfer that loses process intent, or an HPAPI handling gap that […]

Subscribe to our newsletter!

Get notified on our latest news.